source
- Argenx reports positive Phase 3 results for Vyvgart Hytrulo in myositisArgenx announced that its subcutaneous formulation of Vyvgart, named Vyvgart Hytrulo, met the primary endpoint in a late‑stage Phase 3 trial in patients with myositis. The trial combined participa…
- FDA approves Zenbexus for multiple myeloma as NSAI looks to sell MDR notified body unitThe U.S. Food and Drug Administration has granted approval for Zenbexus to be used in the treatment of multiple myeloma, marking a new therapeutic option for patients with this blood cancer. The a…